Microtubule-associated serine/threonine kinase-like (MASTL) is involved in cell proliferation, migration, and invasion and for that reason is considered a relevant therapeutic target for cancer treatment. At the recent ACS Fall meeting, researchers from Pfizer Inc. presented the discovery and characterization of a series of potent and selective MASTL inhibitors for the treatment of cancer.
Imunon Inc. has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for the evaluation of the immunogenicity and efficacy of two Imunon DNA-based Lassa virus vaccine candidates. Under the 3-year agreement, the NIAID will assess the efficacy of Placcine DNA constructs against Lassa virus in guinea pig and non-human primate disease models, including both prime and prime-boost vaccine strategies.
“The size of a chromosome does not correlate with complexity of the sequences within,” Jackson Laboratory professor Charles Lee told BioWorld. Which is why the Y chromosome, which is the runt of the litter as far as human chromosomes are concerned, was the last to be fully sequenced. Now, 20 years after publication of the first near-complete human genome sequence and 16 months after the telomere to telomere (T2T) consortium announced it had completed “gapless assemblies for all chromosomes except Y,” of the human genome, it really is done.
KRAS-mutated tumors were once untreatable. In fact, KRAS was something of a poster child for so-called undruggability. Several laboratories are investigating strategies to address other mutations and uses beyond non-small cell lung cancer (NSCLC) and colorectal cancer. If you can't bind KRAS to block it, use a glue or combine multiple weapons. This is the idea behind two new approaches that target cancers caused by this proto-oncogene.
Eli Lilly & Co. has described pyrrolidine compounds targeting apolipoprotein(a) (Apo[a]) and acting as lipoprotein(a)-lowering agents reported to be useful for the treatment of cardiovascular disorders.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, neurodegeneration, neuroinflammation, pain and psychiatric disorders.
Vivace Therapeutics Inc. has identified transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, polycystic kidney and hepatic fibrosis.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed fused heterocyclic compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, amyotrophic lateral sclerosis and inflammatory disorders, among others.
Peptigrowth Inc. and Orizuru Therapeutics Inc. have entered into a joint development agreement to create a novel synthetic peptide that will replace a recombinant growth factor used in the manufacturing of a regenerative medicine product being developed by Orizuru.
RSS
